rs78756941
Cystic Fibrosis related |
Orientation | plus |
Stabilized | plus |
Geno | Mag | Summary |
---|---|---|
(G;G) | 0 | common in clinvar |
(G;T) | 3 | Cystic Fibrosis carrier |
Make rs78756941(T;T) |
Reference | GRCh38 38.1/141 |
Chromosome | 7 |
Position | 117531115 |
Gene | CFTR |
is a | snp |
is | mentioned by |
dbSNP | rs78756941 |
dbSNP (classic) | rs78756941 |
ClinGen | rs78756941 |
ebi | rs78756941 |
HLI | rs78756941 |
Exac | rs78756941 |
Gnomad | rs78756941 |
Varsome | rs78756941 |
LitVar | rs78756941 |
Map | rs78756941 |
PheGenI | rs78756941 |
Biobank | rs78756941 |
1000 genomes | rs78756941 |
hgdp | rs78756941 |
ensembl | rs78756941 |
geneview | rs78756941 |
scholar | rs78756941 |
rs78756941 | |
pharmgkb | rs78756941 |
gwascentral | rs78756941 |
openSNP | rs78756941 |
23andMe | rs78756941 |
SNPshot | rs78756941 |
SNPdbe | rs78756941 |
MSV3d | rs78756941 |
GWAS Ctlg | rs78756941 |
Max Magnitude | 3 |
rs78756941, also known as 621+1G>T or 489+1G>T, is a SNP in the CFTR gene considered pathogenic for cystic fibrosis.
23andMe has at least three terms in use for rs78756941: i4000314, i5010909 and i6056291.
FTDNA & MyHeritage name: VG07S44961
ClinVar | |
---|---|
Risk | rs78756941(T;T) |
Alt | rs78756941(T;T) |
Reference | Rs78756941(G;G) |
Significance | Pathogenic |
Disease | Cystic fibrosis Hereditary pancreatitis |
Variation | info |
Gene | CFTR |
CLNDBN | Cystic fibrosis Hereditary pancreatitis |
Reversed | 0 |
HGVS | NC_000007.13:g.117171169G>T |
CLNSRC | CFTR2 Cystic Fibrosis Mutation Database |
CLNACC | RCV000043565.8, RCV000360769.1, |
[PMID 1536179] Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis.
[PMID 12007216] Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening.
[PMID 15371902] Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.
[PMID 15371903] CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations.